Elliott Backing Not Enough To Save Pharma Merger

Jan 15 2014 | 11:32am ET

Elliott Management's attack on McKesson Corp.'s proposed acquisition of rival pharmaceutical distributor Celesio appears to have worked too well.

The New York-based hedge fund spent more than a month attacking the US$8.3 billion deal as one that "substantially" undervalued Celesio—before McKesson increased its offer by 2% on the tender offer's last day, coaxing Elliott into accepting. But Elliott may have been the only investor assuaged by the move.

Despite the backing of Franz Haniel & Cie, which owns 50.01% of Celesio, and of Elliott, which owns 22.7%, the deal failed to win the required 75% support from shareholders—even after McKesson gave investors an extra few days to respond.

McKesson said it may consider creating a joint-venture with Celesio following the failure. But Elliott is not likely to be too upset about the deal's failure, despite its last-minute support for the sweetened offer and the drop in Celesio's share price. The hedge fund expressed confidence last month that Celesio "has other paths to maximize shareholder and bondholder value," suggesting that the company's wholesale and pharmacy business be marketed to separate buyers.


In Depth

Dillon Eustace: The Advantages of ICAVs

Feb 11 2016 | 7:51pm ET

As the growth of alternative investment vehicles continues, global asset managers...

Lifestyle

Citadel's Ken Griffin Donates $40M To New York's Museum of Modern Art

Dec 22 2015 | 9:23pm ET

Citadel founder Ken Griffin has donated $40 million to New York’s Museum of Modern...

Guest Contributor

Hedging Against Reputational Risk in the 21st Century

Feb 12 2016 | 7:18pm ET

For investors, the first step in researching a new fund or manager is to google...